166 related articles for article (PubMed ID: 26524088)
1. Octreotide-Mediated Tumor-Targeted Drug Delivery via a Cleavable Doxorubicin-Peptide Conjugate.
Lelle M; Kaloyanova S; Freidel C; Theodoropoulou M; Musheev M; Niehrs C; Stalla G; Peneva K
Mol Pharm; 2015 Dec; 12(12):4290-300. PubMed ID: 26524088
[TBL] [Abstract][Full Text] [Related]
2. Effect of ligand density and PEG modification on octreotide-targeted liposome via somatostatin receptor in vitro and in vivo.
Li H; Yuan D; Sun M; Ping Q
Drug Deliv; 2016 Nov; 23(9):3562-3572. PubMed ID: 27432585
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin Receptor-Mediated Tumor-Targeting Nanocarriers Based on Octreotide-PEG Conjugated Nanographene Oxide for Combined Chemo and Photothermal Therapy.
Zhang X; Yang C; Zhou J; Huo M
Small; 2016 Jul; 12(26):3578-90. PubMed ID: 27244649
[TBL] [Abstract][Full Text] [Related]
4. Comparison of active and passive targeting of doxorubicin for somatostatin receptor 2 positive tumor models by octreotide-modified HPMA copolymer-doxorubicin conjugates.
He S; Zhou Z; Li L; Yang Q; Yang Y; Guan S; Zhang J; Zhu X; Jin Y; Huang Y
Drug Deliv; 2016; 23(1):285-96. PubMed ID: 24865288
[TBL] [Abstract][Full Text] [Related]
5. Novel cleavable cell-penetrating peptide-drug conjugates: synthesis and characterization.
Lelle M; Frick SU; Steinbrink K; Peneva K
J Pept Sci; 2014 May; 20(5):323-33. PubMed ID: 24677287
[TBL] [Abstract][Full Text] [Related]
6. Octreotide-mediated tumor cell uptake and intracellular pH-responsive drug delivery of the self-assembly supramolecular nanocarrier.
Niu J; Huang A; Xiao Y; Su Z; Li H; Ping Q; Bao X; Li S; Chen Y; Sun M
J Drug Target; 2013 May; 21(5):415-26. PubMed ID: 23597028
[TBL] [Abstract][Full Text] [Related]
7. Octreotide-modification enhances the delivery and targeting of doxorubicin-loaded liposomes to somatostatin receptors expressing tumor in vitro and in vivo.
Sun M; Wang Y; Shen J; Xiao Y; Su Z; Ping Q
Nanotechnology; 2010 Nov; 21(47):475101. PubMed ID: 21030757
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel-octreotide conjugates in tumor growth inhibition of A549 human non-small cell lung cancer xenografted into nude mice.
Shen H; Hu D; Du J; Wang X; Liu Y; Wang Y; Wei JM; Ma D; Wang P; Li L
Eur J Pharmacol; 2008 Dec; 601(1-3):23-9. PubMed ID: 18983839
[TBL] [Abstract][Full Text] [Related]
9. Tumor targeted delivery of octreotide-periplogenin conjugate: Synthesis, in vitro and in vivo evaluation.
Zhang HY; Xu WQ; Wang YW; Omari-Siaw E; Wang Y; Zheng YY; Cao X; Tong SS; Yu JN; Xu XM
Int J Pharm; 2016 Apr; 502(1-2):98-106. PubMed ID: 26899980
[TBL] [Abstract][Full Text] [Related]
10. Cancer-targeted delivery systems based on peptides.
Chatzisideri T; Leonidis G; Sarli V
Future Med Chem; 2018 Sep; 10(18):2201-2226. PubMed ID: 30043641
[TBL] [Abstract][Full Text] [Related]
11. Somatostatin receptor-mediated tumor-targeting drug delivery using octreotide-PEG-deoxycholic acid conjugate-modified N-deoxycholic acid-O, N-hydroxyethylation chitosan micelles.
Huo M; Zou A; Yao C; Zhang Y; Zhou J; Wang J; Zhu Q; Li J; Zhang Q
Biomaterials; 2012 Sep; 33(27):6393-407. PubMed ID: 22704599
[TBL] [Abstract][Full Text] [Related]
12. Effect of octreotide surface density on receptor-mediated endocytosis in vitro and anticancer efficacy of modified nanocarrier in vivo after optimization.
Su Z; Shi Y; Xiao Y; Sun M; Ping Q; Zong L; Li S; Niu J; Huang A; You W; Chen Y; Chen X; Fei J; Tian J
Int J Pharm; 2013 Apr; 447(1-2):281-92. PubMed ID: 23396258
[TBL] [Abstract][Full Text] [Related]
13. Well-Defined Redox-Sensitive Polyethene Glycol-Paclitaxel Prodrug Conjugate for Tumor-Specific Delivery of Paclitaxel Using Octreotide for Tumor Targeting.
Yin T; Wu Q; Wang L; Yin L; Zhou J; Huo M
Mol Pharm; 2015 Aug; 12(8):3020-31. PubMed ID: 26086430
[TBL] [Abstract][Full Text] [Related]
14. Enhancing cancer targeting and anticancer activity by a stimulus-sensitive multifunctional polymer-drug conjugate.
Tu Y; Zhu L
J Control Release; 2015 Aug; 212():94-102. PubMed ID: 26113423
[TBL] [Abstract][Full Text] [Related]
15. Investigation of cancer cell lines for peptide receptor-targeted drug development.
Sun L; Luo J; Mackey LV; Morris LM; Franko-Tobin LG; LePage KT; Coy DH
J Drug Target; 2011 Sep; 19(8):719-30. PubMed ID: 21830941
[TBL] [Abstract][Full Text] [Related]
16. Cell-specific delivery of a chemotherapeutic to lung cancer cells.
Zhou X; Chang YC; Oyama T; McGuire MJ; Brown KC
J Am Chem Soc; 2004 Dec; 126(48):15656-7. PubMed ID: 15571383
[TBL] [Abstract][Full Text] [Related]
17. Engineered peptides for the development of actively tumor targeted liposomal carriers of doxorubicin.
Shahin M; Soudy R; El-Sikhry H; Seubert JM; Kaur K; Lavasanifar A
Cancer Lett; 2013 Jul; 334(2):284-92. PubMed ID: 23073474
[TBL] [Abstract][Full Text] [Related]
18. Temperature-triggered tumor-specific delivery of anticancer agents by cRGD-conjugated thermosensitive liposomes.
Kim MS; Lee DW; Park K; Park SJ; Choi EJ; Park ES; Kim HR
Colloids Surf B Biointerfaces; 2014 Apr; 116():17-25. PubMed ID: 24441178
[TBL] [Abstract][Full Text] [Related]
19. Octreotide-modified N-octyl-O, N-carboxymethyl chitosan micelles as potential carriers for targeted antitumor drug delivery.
Zou A; Huo M; Zhang Y; Zhou J; Yin X; Yao C; Zhu Q; Zhang M; Ren J; Zhang Q
J Pharm Sci; 2012 Feb; 101(2):627-40. PubMed ID: 22083725
[TBL] [Abstract][Full Text] [Related]
20. Overcoming drug resistance by cell-penetrating peptide-mediated delivery of a doxorubicin dimer with high DNA-binding affinity.
Lelle M; Freidel C; Kaloyanova S; Tabujew I; Schramm A; Musheev M; Niehrs C; Müllen K; Peneva K
Eur J Med Chem; 2017 Apr; 130():336-345. PubMed ID: 28273560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
